Enhancing crystallization with binding partners, symmetry and diversity

通过结合伙伴、对称性和多样性增强结晶

基本信息

项目摘要

DESCRIPTION (provided by applicant): The bottleneck in structure determination by X-ray crystallography is crystallization, where roughly 70% of purified proteins fail. Two major reasons proteins fail to enter the crystalline state are having too few lattice contacts, and having multipe conformations, often the result of missing partner proteins. The purpose of this project is to overcome barriers to crystallization. The key overall ideas in this project are that crystallizatio of a macromolecule or complex can be improved by (1) presenting this macromolecule in a form that is highly suitable for crystallization and (2) creating many different forms of the macromolecule. These themes of optimizing crystallizability and variation are central to all three components of this projects. The innovation new methods we propose to develop will use a combination of natural binding partners and binding modules to improve crystallization of a target macromolecule by (1) creating many different forms of a molecule to crystallize and (2) finding a natural partner macromolecule that stabilizes and enhances the crystallizability of a target macromolecule. Many forms of a molecule will be created using a panel of symmetry-forming modules that can be linked to the target molecule. These modules will be antibody- or green fluorescent protein-based. Natural binding partners will be found with a combination of novel bioinformatics and experimental approaches. The transformative methods are scalable, synergistic, and offer the potential of accelerating results in both structural biology and structual genomics by providing a molecular toolkit for diversifying the potential crystallization arrangements and symmetries of targeted proteins. This program project will be carried out by our UCLA/ Los Alamos team as three tightly integrated subprojects, each involving researchers from both UCLA and Los Alamos. This work will lead to methods that will be used by the structural biology community to determine structures of proteins that will increase our understanding of human health and our ability to cure human disease.
描述(由申请人提供):X 射线晶体学确定结构的瓶颈是结晶,大约 70% 的纯化蛋白质在结晶过程中失败。蛋白质无法进入结晶状态的两个主要原因是晶格接触太少,以及具有多种构象,这通常是缺少伴侣蛋白质的结果。该项目的目的是克服结晶障碍。该项目的关键总体想法是,可以通过以下方式改进大分子或复合物的结晶:(1)以高度适合结晶的形式呈现该大分子;以及(2)创建该大分子的许多不同形式。这些优化结晶性和变化的主题是该项目所有三个组成部分的核心。我们建议开发的创新方法将使用天然结合伴侣和结合模块的组合来改善目标大分子的结晶,方法是:(1)创建许多不同形式的分子进行结晶;(2)找到稳定和增强目标大分子结晶性的天然伴侣大分子。许多形式的分子将使用一组可连接到目标分子的对称形成模块来创建。这些模块将基于抗体或绿色荧光蛋白。结合新颖的生物信息学和实验方法将发现天然结合伴侣。这些变革性方法具有可扩展性、协同性,并且通过提供使目标蛋白质的潜在结晶排列和对称性多样化的分子工具包,有可能加速结构生物学和结构基因组学的结果。该计划项目将由我们的加州大学洛杉矶分校/洛斯阿拉莫斯团队作为三个紧密结合的子项目来实施,每个子项目都涉及加州大学洛杉矶分校和洛斯阿拉莫斯的研究人员。这项工作将带来结构生物学界用来确定蛋白质结构的方法,从而增加我们对人类健康的理解和治疗人类疾病的能力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW BRADBURY其他文献

ANDREW BRADBURY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW BRADBURY', 18)}}的其他基金

Enhancing crystallization with binding partners, symmetry and diversity
通过结合伙伴、对称性和多样性增强结晶
  • 批准号:
    8666771
  • 财政年份:
    2012
  • 资助金额:
    $ 115.46万
  • 项目类别:
Enhancing crystallization with binding partners, symmetry and diversity
通过结合伙伴、对称性和多样性增强结晶
  • 批准号:
    8268582
  • 财政年份:
    2012
  • 资助金额:
    $ 115.46万
  • 项目类别:
A high throughput pipeline to select renewable recombinant polyclonal antibodies
选择可再生重组多克隆抗体的高通量管道
  • 批准号:
    8335448
  • 财政年份:
    2011
  • 资助金额:
    $ 115.46万
  • 项目类别:
ANALYSIS AND SORTING OF BACTERIAL LIBRARY EXPRESSING GFP
表达GFP的细菌文库分析与排序
  • 批准号:
    8361751
  • 财政年份:
    2011
  • 资助金额:
    $ 115.46万
  • 项目类别:
SWITCHING OF FLUORESCENCE LIFETIME UPON FUOROBODY BINDING
荧光体结合时荧光寿命的切换
  • 批准号:
    8361766
  • 财政年份:
    2011
  • 资助金额:
    $ 115.46万
  • 项目类别:
A high throughput pipeline to select renewable recombinant polyclonal antibodies
选择可再生重组多克隆抗体的高通量管道
  • 批准号:
    8533069
  • 财政年份:
    2011
  • 资助金额:
    $ 115.46万
  • 项目类别:
A high throughput pipeline to select renewable recombinant polyclonal antibodies
选择可再生重组多克隆抗体的高通量管道
  • 批准号:
    8223869
  • 财政年份:
    2011
  • 资助金额:
    $ 115.46万
  • 项目类别:
A high throughput pipeline to select renewable recombinant polyclonal antibodies
选择可再生重组多克隆抗体的高通量管道
  • 批准号:
    8520300
  • 财政年份:
    2011
  • 资助金额:
    $ 115.46万
  • 项目类别:
ANALYSIS AND SORTING OF BACTERIAL LIBRARY EXPRESSING GFP
表达GFP的细菌文库分析与排序
  • 批准号:
    8169387
  • 财政年份:
    2010
  • 资助金额:
    $ 115.46万
  • 项目类别:
SWITCHING OF FLUORESCENCE LIFETIME UPON FUOROBODY BINDING
荧光体结合时荧光寿命的切换
  • 批准号:
    8169402
  • 财政年份:
    2010
  • 资助金额:
    $ 115.46万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 115.46万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 115.46万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 115.46万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 115.46万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 115.46万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 115.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 115.46万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 115.46万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 115.46万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 115.46万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了